Skip to main content
OpenTrials

Clinical trial condition

Clinical Stage III Cutaneous Melanoma AJCC v8

Explore clinical trials studying Clinical Stage III Cutaneous Melanoma AJCC v8. Study availability and eligibility vary by location and protocol.

31 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Clinical Stage III Cutaneous Melanoma AJCC v8 trial results

Completed

Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

NCT04593277

Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, +38 more
Locations
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

NCT03033576

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, +3 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 638 locations
View Trial Details
Completed

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866

Conditions
AIDS-Related Non-Hodgkin Lymphoma, Adenocarcinoma, Blood-Borne Infections, +76 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Zuckerberg San Francisco General Hospital San Francisco, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
  • Yale University New Haven, Connecticut, United States
View Trial Details
Active, Not Recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

NCT02506153

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma, +18 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Virginia G Piper Cancer Care-Del Camino Scottsdale, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 576 locations
View Trial Details
Active, Not Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT04462406

Conditions
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, +8 more
Locations
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
View all 482 locations
View Trial Details
Active, Not Recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma, +14 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 839 locations
View Trial Details
Active, Not Recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019

Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, +1 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
View all 816 locations
View Trial Details

Related conditions